These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 26798051)

  • 1. Safety of Intranasal Quadrivalent Live Attenuated Influenza Vaccine (QLAIV) in Children and Adolescents: A Pilot Prospective Cohort Study in England.
    McNaughton R; Lynn E; Osborne V; Coughtrie A; Layton D; Shakir S
    Drug Saf; 2016 Apr; 39(4):323-33. PubMed ID: 26798051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced Safety Surveillance of Seasonal Quadrivalent Influenza Vaccines in English Primary Care: Interim Analysis.
    de Lusignan S; Dos Santos G; Byford R; Schuind A; Damaso S; Shende V; McGee C; Yonova I; Ferreira F
    Adv Ther; 2018 Aug; 35(8):1199-1214. PubMed ID: 29995300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the safety of live attenuated influenza vaccine (LAIV) in children and adolescents with asthma and high-risk conditions: a population-based prospective cohort study conducted in England with the Clinical Practice Research Datalink.
    Caspard H; Steffey A; Mallory RM; Ambrose CS
    BMJ Open; 2018 Dec; 8(12):e023118. PubMed ID: 30530581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Live attenuated influenza vaccine, trivalent, is safe in healthy children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in a community-based, nonrandomized, open-label trial.
    Piedra PA; Gaglani MJ; Riggs M; Herschler G; Fewlass C; Watts M; Kozinetz C; Hessel C; Glezen WP
    Pediatrics; 2005 Sep; 116(3):e397-407. PubMed ID: 16140685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intranasal live attenuated seasonal influenza vaccine: does not challenge current practice.
    Prescrire Int; 2013 Sep; 22(141):201-4. PubMed ID: 24171209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of quadrivalent live attenuated influenza vaccine in subjects aged 2-49years.
    Baxter R; Eaton A; Hansen J; Aukes L; Caspard H; Ambrose CS
    Vaccine; 2017 Mar; 35(9):1254-1258. PubMed ID: 28162825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post-authorisation passive enhanced safety surveillance of seasonal influenza vaccines: protocol of a pilot study in England.
    de Lusignan S; Dos Santos G; Correa A; Haguinet F; Yonova I; Lair F; Byford R; Ferreira F; Stuttard K; Chan T
    BMJ Open; 2017 May; 7(5):e015469. PubMed ID: 28515198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Uptake and impact of a new live attenuated influenza vaccine programme in England: early results of a pilot in primary school-age children, 2013/14 influenza season.
    Pebody RG; Green HK; Andrews N; Zhao H; Boddington N; Bawa Z; Durnall H; Singh N; Sunderland A; Letley L; Ellis J; Elliot AJ; Donati M; Smith GE; de Lusignan S; Zambon M
    Euro Surveill; 2014 Jun; 19(22):. PubMed ID: 24925457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of quadrivalent seasonal influenza vaccines in England.
    Thorrington D; van Leeuwen E; Ramsay M; Pebody R; Baguelin M
    BMC Med; 2017 Sep; 15(1):166. PubMed ID: 28882149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma.
    Fleming DM; Crovari P; Wahn U; Klemola T; Schlesinger Y; Langussis A; Øymar K; Garcia ML; Krygier A; Costa H; Heininger U; Pregaldien JL; Cheng SM; Skinner J; Razmpour A; Saville M; Gruber WC; Forrest B;
    Pediatr Infect Dis J; 2006 Oct; 25(10):860-9. PubMed ID: 17006278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nasal spray live attenuated influenza vaccine: the first experience in Italy in children and adolescents during the 2020-21 season.
    Gasparini C; Acunzo M; Biuso A; Roncaglia S; Migliavacca F; Borriello CR; Bertolini C; Allen MR; Orenti A; Boracchi P; Zuccotti GV
    Ital J Pediatr; 2021 Nov; 47(1):225. PubMed ID: 34774062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of Russian-backbone seasonal trivalent, live-attenuated influenza vaccine in a phase II randomized placebo-controlled clinical trial among children in urban Bangladesh.
    Ortiz JR; Goswami D; Lewis KD; Sharmeen AT; Ahmed M; Rahman M; Rahman MZ; Feser J; Neuzil KM; Brooks WA
    Vaccine; 2015 Jun; 33(29):3415-21. PubMed ID: 25917680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and tolerability of cold-adapted influenza vaccine, trivalent, in infants younger than 6 months of age.
    Vesikari T; Karvonen A; Smith HM; Dunning A; Razmpour A; Saville MK; Gruber WC; Forrest BD
    Pediatrics; 2008 Mar; 121(3):e568-73. PubMed ID: 18299305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Seasonal influenza vaccines.
    Fiore AE; Bridges CB; Cox NJ
    Curr Top Microbiol Immunol; 2009; 333():43-82. PubMed ID: 19768400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Shedding of Ann Arbor strain live attenuated influenza vaccine virus in children 6-59 months of age.
    Mallory RM; Yi T; Ambrose CS
    Vaccine; 2011 Jun; 29(26):4322-7. PubMed ID: 21513761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections.
    Ashkenazi S; Vertruyen A; Arístegui J; Esposito S; McKeith DD; Klemola T; Biolek J; Kühr J; Bujnowski T; Desgrandchamps D; Cheng SM; Skinner J; Gruber WC; Forrest BD;
    Pediatr Infect Dis J; 2006 Oct; 25(10):870-9. PubMed ID: 17006279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trivalent live attenuated intranasal influenza vaccine administered during the 2003-2004 influenza type A (H3N2) outbreak provided immediate, direct, and indirect protection in children.
    Piedra PA; Gaglani MJ; Kozinetz CA; Herschler GB; Fewlass C; Harvey D; Zimmerman N; Glezen WP
    Pediatrics; 2007 Sep; 120(3):e553-64. PubMed ID: 17698577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced passive surveillance of influenza vaccination in England, 2016-2017- an observational study using an adverse events reporting card.
    de Lusignan S; Ferreira F; Damaso S; Byford R; Pathirannehelage S; Yeakey A; Yonova I; Schuind A; Dos Santos G
    Hum Vaccin Immunother; 2019; 15(5):1048-1059. PubMed ID: 30648923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse Events of Interest Following Influenza Vaccination in the First Season of Adjuvanted Trivalent Immunization: Retrospective Cohort Study.
    de Lusignan S; Tsang RSM; Akinyemi O; Lopez Bernal J; Amirthalingam G; Sherlock J; Smith G; Zambon M; Howsam G; Joy M
    JMIR Public Health Surveill; 2022 Mar; 8(3):e25803. PubMed ID: 35343907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The safety and effectiveness of self-administration of intranasal live attenuated influenza vaccine in adults.
    Ambrose CS; Wu X
    Vaccine; 2013 Jan; 31(6):857-60. PubMed ID: 23261050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.